IntelGenx completes US$12.6 million equity offering

2 minute read
22 October 2018

On Oct. 22, 2018, IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT), a leading oral drug delivery company, announced that it had closed its offering of units for gross proceeds of approximately US$12 million in the United States and the Canadian provinces of Alberta, British Columbia, Manitoba, Ontario and Quebec. The units were distributed under a final prospectus supplement to the US registration statement on Form S-3 (File No. 333-227498), which was declared effective on Oct. 15, 2018; a final Canadian MJDS prospectus supplement to the Canadian MJDS short-form base shelf dated Oct. 18, 2018 was filed by IntelGenx in connection with the offering.

The offering was conducted, on a best efforts basis, by Echelon Wealth Partners Inc. in its capacity as the exclusive placement agent for the units offered in Canada and H.C. Wainwright & Co. in its capacity as the exclusive placement agent for the units offered in the United States.

On Oct, 26, 2018, IntelGenx announced that Echelon had exercised its option to purchase further units, resulting in additional gross proceeds to IntelGenx of approximately US$0.6 million.

Gowling WLG advised the agents with a team led by Andre Poles and Ian Mitchell, and included Josh Rosen and Stephen Franchetto (corporate/securities), and Anita Nador and Jasleen Chahal (IP), assisted by student-at-law Ryan Cohen.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.

Related   Capital Markets